Indapta Therapeutics

Indapta scientists will be speaking at this year's Innate Killer Conference, March 3-5th in San Diego. Matthew Collinson-Pautz, Director, Preclinical & Translational Research will chair a session entitled, "Understanding the Inherent Advantages of NK Biology to Spearhead Future Development." Stefanie Mandl-Cashman, Chief Scientific Officer will speak on the application of NK cells to autoimmune disease. Mark Frohlich, CEO, will speak on considerations for developing a combination product. We hope to see you there! https://lnkd.in/gAupHqym https://lnkd.in/gmQfx6R3

We're thrilled to share that our g-natural killer (g-NK) cell therapy, IDP-023, has received FDA IND clearance for a Phase 1 trial in progressive multiple sclerosis, bringing us one step closer to expanding into autoimmune disease. In partnership with Stanford University and University of California, San Francisco we are exploring how IDP-023, in combination with ocrelizumab, can redefine treatment approaches and provide more options for MS patients and their care teams. Learn more here:

We are excited to share that Iris Marchal profiled Indapta in a new editor’s pick feature. Our CSO Stefanie Mandl-Cashman, Ph.D. shares how focusing on the power of naturally occurring NK cells, we're able to bring new hope to those faced with hard-to-treat conditions like cancer and autoimmune disorders.   Read the piece to learn more about our IND filings and expanding pipeline! https://lnkd.in/g4PqPTht

As the Founder, Founding CEO and currently the COO of Indapta, I am delighted that Mark Frohlich, our CEO, had this opportunity to highlight that the initial patients treated in our clinical trial in multiple myeloma and lymphoma had disease responses- some of them quite dramatic disease responses. This early clinical evidence of efficacy at our lowest dose and without a mAb encourages us that this could translate into a meaningful benefit for patients. That is what it is all about, saving lives - one cancer patient at a time. We are all quite hopeful that this therapy will also help patients suffering from auto immune disease.

CheckRare, a publisher focused on rare diseases, just released a recent interview with our CEO, Dr. Mark Frohlich. He discusses how Indapta’s differentiated NK cell therapy platform has the potential to address high unmet need diseases, including advanced cancer and autoimmune diseases. Find it at https://lnkd.in/emCdu_B2.

Webinar alert! This Tuesday, June 25th at 8AM PT/11AM ET our CEO, Dr. Mark Frohlich will be participating in a webinar on emerging cell therapies, hosted by Genetic Engineering & Biotechnology News. Dr. Frohlich will discuss how NK cell therapy and Indapta’s g-NK cell platform in particular can address some of the challenges of current cell therapy approaches. You can view the webinar and participate in the Q&A at https://ow.ly/vyfw50Sg8Z4. Hope you can join us!

📚 Add this insightful read to your list! Check out the eBook "Allogeneic Cell Therapy: From Clinical Concept to Viable Product," published by BioProcess International. This comprehensive guide offers a deep dive into the revolutionary field of allogeneic cell therapies.   The eBook features insights from leading experts, including our very own CEO, Mark Frohlich where he discusses the transformative potential of Indapta’s natural killer (NK) cell-based therapies in treating cancer and autoimmune diseases. Read the eBook here: https://lnkd.in/ggAz2PPa

Our CEO, Dr. Mark Frohlich, was recently interviewed by Michael Pietrack for the Pharmaverse Podcast, in which he discusses his career in drug development, the future of immuno-oncology, leadership, mentoring and career development. Here is the link to the episode: https://lnkd.in/gtkRAZCx

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded Indapta a $4.5M research development award in support of the Phase 1 trial in multiple myeloma and non-Hodgkin's lymphoma. https://lnkd.in/geW_xaqN